Abstract: ObjectiveTo explore the expressions and clinical values of serum microRNA1395p (miR1395p) in diagnosis and prognosis of patients with ovarian cancer. MethodsFrom March 2009 to December 2011, a total of 34 patients with serous ovarian cancer and 34 female health examiners were collected in our hospital. The expressions of serum miR1395p before and after operation were detected in 34 patients with ovarian cancer and 34 healthy women by realtime quantitative polymerase chain reaction (RTqPCR). The data was analyzed by ttest. The clinical values of serum miR1395p in diagnosis and prognosis of patients with ovarian cancer were analyzed. ResultsThe expression of serum miR1395p in patients with ovarian cancer (9.45±0.40) was significantly higher than that in healthy controls (3.56±0.10), with a significant difference (t=14.340, P＜0.001). The expression of miR1395p at 1 month after operation of patients with ovarian cancer (5.53±0.49) was lower than that before operation, with a significant difference (t=7.800, P＜0.001). The expression of serum miR1395p was correlated with lymph node metastasis (P=0.038), but was not correlated with age (P=0.728), clinical stage (P=0.118), tumor size (P=0.732) and differentiation (P=0.071). KaplanMeier survival curve revealed that the median survival time of ovarian cancer patients with low serum miR1395p expression (44.9 months) was longer than that of patients with high serum miR1395p expression (25.9 months), with a significant difference (χ2=5.721, P=0.017). ConclusionThe expression of miR1395p is increased significantly in the serum of patients with ovarian cancer, which can be used as a potential biomarker for diagnosis and prognosis of patients with ovarian cancer.

Key words: MicroRNAs, Ovarian neoplasms, Serum, Diagnosis, Prognosis